Pfizer executives say Wall Street analysts haven’t understood just how powerful a hit the company’s Covid-19 products will take this year.
That’s the explanation the company’s chief financial officer, David Denton, gave Barron’s on Tuesday, as to why the 2023 earnings guidance of between $3.25 and $3.45 per share, which he issued earlier in the day, was so far below the $4.33 per share consensus estimate.
